Goodwin advised Sage Therapeutics on the transaction Sage Therapeutics (NASDAQ:SAGE) executed the pricing of an underwritten public offering of 3,506,098 shares of its common stock at…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
